Education
About Us
Working with TipRanks
Follow Us
Eton Pharmaceuticals Inc (ETON)
NASDAQ:ETON
ETON Stock Chart & Stats
$16.82
-$0.03(-0.25%)
At close: 4:00 PM EST
$16.82
-$0.03(-0.25%)
Day’s Range― - ―
52-Week Range$10.20 - $23.00
Previous CloseN/A
Volume127.06K
Average Volume (3M)276.69K
Market Cap
$462.87M
Enterprise Value$578.14M
Total Cash (Recent Filing)$37.12M
Total Debt (Recent Filing)$3.26M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Mar 12, 2026EPS Estimate
0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.04
Shares Outstanding26,817,535
10 Day Avg. Volume361,416
30 Day Avg. Volume276,689
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)14.12
Price to Sales (P/S)8.84
P/FCF Ratio365.77
Enterprise Value/Market Cap1.25
Enterprise Value/Revenue8.22
Enterprise Value/Gross Profit16.01
Enterprise Value/Ebitda436.99
Forecast
1Y Price Target
$35.00Price Target Upside108.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.17
Revenue Forecast (FY)$78.50M
Bulls Say, Bears Say
Bulls Say
Acquisition StrategyManagement expects to execute two acquisition transactions to add to the current commercial portfolio which could provide an upside to current projections.
Product RelaunchThe US relaunch of Increlex continues to beat management’s expectations.
Revenue GrowthEton Pharmaceuticals reported yet another consecutive quarter of growth with 3Q25 revenues of $22.5M, higher than consensus estimate of $20.5M.
Bears Say
Eton Pharmaceuticals News
ETON FAQ
What was Eton Pharmaceuticals Inc’s price range in the past 12 months?
Eton Pharmaceuticals Inc lowest stock price was $10.20 and its highest was $23.00 in the past 12 months.
What is Eton Pharmaceuticals Inc’s market cap?
Eton Pharmaceuticals Inc’s market cap is $462.87M.
When is Eton Pharmaceuticals Inc’s upcoming earnings report date?
Eton Pharmaceuticals Inc’s upcoming earnings report date is Mar 12, 2026 which is in 111 days.
How were Eton Pharmaceuticals Inc’s earnings last quarter?
Eton Pharmaceuticals Inc released its earnings results on Nov 06, 2025. The company reported $0.04 earnings per share for the quarter, missing the consensus estimate of $0.09 by -$0.05.
Is Eton Pharmaceuticals Inc overvalued?
According to Wall Street analysts Eton Pharmaceuticals Inc’s price is currently Undervalued.
Does Eton Pharmaceuticals Inc pay dividends?
Eton Pharmaceuticals Inc does not currently pay dividends.
What is Eton Pharmaceuticals Inc’s EPS estimate?
Eton Pharmaceuticals Inc’s EPS estimate is 0.2.
How many shares outstanding does Eton Pharmaceuticals Inc have?
Eton Pharmaceuticals Inc has 26,817,535 shares outstanding.
What happened to Eton Pharmaceuticals Inc’s price movement after its last earnings report?
Eton Pharmaceuticals Inc reported an EPS of $0.04 in its last earnings report, missing expectations of $0.09. Following the earnings report the stock price went down -11.703%.
Which hedge fund is a major shareholder of Eton Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in ETON
Eton Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$35.00 (108.09% Upside)
$35.00 (108.09% Upside)
Blogger Sentiment
Bullish
ETON Sentiment 75%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $673.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 28.7%
Last 30 Days ▼ 31.3%
Last 30 Days ▼ 31.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
71.48%
12-Months-Change
Fundamentals
Return on Equity
-34.17%
Trailing 12-Months
Asset Growth
191.59%
Trailing 12-Months
Company Description
Eton Pharmaceuticals Inc
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
ETON Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Eton Pharmaceuticals experienced substantial revenue growth and strong performance from key products, leading to positive cash flow generation and profitability. However, the company faced challenges with net income, patient count for INCRELEX, and FDA restrictions on KHINDIVI. Despite these challenges, the overall outlook remains positive with strategic initiatives underway.View all ETON earnings summariesETON Stock 12 Month Forecast
Average Price Target
$35.00
▲(108.09% Upside)
Technical Analysis
Ownership Overview
25.28% Insiders
8.30% Mutual Funds
34.45% Other Institutional Investors
23.62% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---